The oncogenic role of hepatitis delta virus in hepatocellular carcinoma

by Marc Puigvehí, Carlos Moctezuma-Velázquez, Augusto Villanueva, Josep M. Llovet
Published 2019-08-01

Liver Cancer Disparities in New York City: A Neighborhood View of Risk and Harm Reduction Factors

by Geetanjali R. Kamath, Geetanjali R. Kamath, Geetanjali R. Kamath, Emanuela Taioli, Emanuela Taioli, Emanuela Taioli, Natalia N. Egorova, Josep M. Llovet, Josep M. Llovet, Josep M. Llovet, Ponni V. Perumalswami, Jeffrey J. Weiss, Myron Schwartz, Stanley Ewala, Nina A. Bickell, Nina A. Bickell, Nina A. Bickell
Published 2018-06-01

Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2)

by Masatoshi Kudo, Richard S. Finn, Manabu Morimoto, Kun-Ming Rau, Masafumi Ikeda, Chia-Jui Yen, Peter R. Galle, Josep M. Llovet, Bruno Daniele, Ho Yeong Lim, David W. McIlwain, Reigetsu Yoshikawa, Kenichi Nakamura, Kun Liang, Chunxiao Wang, Paolo Abada, Ryan C. Widau, Andrew X. Zhu
Published 2021-07-01

Transcriptomic characterization of cancer-testis antigens identifies MAGEA3 as a driver of tumor progression in hepatocellular carcinoma.

by Amanda J Craig, Teresa Garcia-Lezana, Marina Ruiz de Galarreta, Carlos Villacorta-Martin, Edgar G Kozlova, Sebastiao N Martins-Filho, Johann von Felden, Mehmet Eren Ahsen, Erin Bresnahan, Gabriela Hernandez-Meza, Ismail Labgaa, Delia D'Avola, Myron Schwartz, Josep M Llovet, Daniela Sia, Swan Thung, Bojan Losic, Amaia Lujambio, Augusto Villanueva
Published 2021-06-01

R‐spondin 2 Drives Liver Tumor Development in a Yes‐Associated Protein‐Dependent Manner

by Caitlin B. Conboy, Germán L. Vélez‐Reyes, Barbara R. Tschida, Hsiangyu Hu, Gabriel Kaufmann, Nicholas Koes, Bryant Keller, Clara Alsinet, Helena Cornellà, Roser Pinyol, Juan E. Abrahante, Nuri A. Temiz, Michael A. Linden, Khalid Amin, Timothy P. Kuka, Vincent W. Keng, Josep M. Llovet, Timothy K. Starr, David A. Largaespada
Published 2019-11-01

YAP Inhibition Restores Hepatocyte Differentiation in Advanced HCC, Leading to Tumor Regression

by Julien Fitamant, Filippos Kottakis, Samira Benhamouche, Helen S. Tian, Nicolas Chuvin, Christine A. Parachoniak, Julia M. Nagle, Rushika M. Perera, Marjorie Lapouge, Vikram Deshpande, Andrew X. Zhu, Albert Lai, Bosun Min, Yujin Hoshida, Joseph Avruch, Daniela Sia, Genís Campreciós, Andrea I. McClatchey, Josep M. Llovet, David Morrissey, Lakshmi Raj, Nabeel Bardeesy
Published 2015-03-01

Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2

by Masatoshi Kudo, Peter R. Galle, Giovanni Brandi, Yoon-Koo Kang, Chia-Jui Yen, Richard S. Finn, Josep M. Llovet, Eric Assenat, Philippe Merle, Stephen L. Chan, Daniel H. Palmer, Masafumi Ikeda, Tatsuya Yamashita, Arndt Vogel, Yi-Hsiang Huang, Paolo B. Abada, Reigetsu Yoshikawa, Kenta Shinozaki, Chunxiao Wang, Ryan C. Widau, Andrew X. Zhu
Published 2021-04-01

Intratumoral heterogeneity and clonal evolution in liver cancer

by Bojan Losic, Amanda J. Craig, Carlos Villacorta-Martin, Sebastiao N. Martins-Filho, Nicholas Akers, Xintong Chen, Mehmet E. Ahsen, Johann von Felden, Ismail Labgaa, Delia DʹAvola, Kimaada Allette, Sergio A. Lira, Glaucia C. Furtado, Teresa Garcia-Lezana, Paula Restrepo, Ashley Stueck, Stephen C. Ward, Maria I. Fiel, Spiros P. Hiotis, Ganesh Gunasekaran, Daniela Sia, Eric E. Schadt, Robert Sebra, Myron Schwartz, Josep M. Llovet, Swan Thung, Gustavo Stolovitzky, Augusto Villanueva
Published 2020-01-01